Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.2.1.23 (beta-galactosidase)
 14,648 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The effect of indomethacin on bone resorption was studied in an organ culture system, using calvarial bones from 6--7-day-old mice. It was found that indomethacin inhibited spontaneous bone resorption, as estimated by decreased release of 45Ca, Ca2+ and Pi. Indomethacin reduced the release of beta-glucuronidase, beta-galactosidase and beta-N-acetylglucosaminidase, diminished glucose consumption and lactate production, but showed no effect on the release of lactate dehydrogenase. No inhibitory effect of indomethacin on the release of 45Ca stimulated by parathyroid hormone, prostaglandin E2 or 1 alpha(OH)D3 could be registered. 5,8,11,14-eicosatetraynoic acid, an inhibitor of both cyclo- and lipoxygenase pathway of arachidonate metabolism, reduced the spontaneous release of 45Ca, whereas the selective lipoxygenase inhibitor 5,8,11-eicosatriynoic acid was without effect. The results presented indicate that indomethacin may have an inhibitory effect upon the osteoclasts, probably by decreased metabolism of arachidonic acid via the cyclo-oxygenase pathway. A possible relationship between this finding and the pathogenesis of rapid destruction of articular bone in osteoarthritic patients treated with indomethacin is discussed.
 ...
PMID:Indomethacin inhibits bone resorption and lysosomal enzyme release from bone in organ culture. 745 22

Indomethacin, a potent anti-inflammatory drug, activates the DNA-binding activity of human heat shock transcription factor 1 (HSF1), but this is insufficient to elevate heat shock gene expression. However, indomethacin pretreatment leads to a complete heat shock response at temperatures that are by themselves insufficient. Here, we showed that the heat-induced loss of enzymatic activity of a nuclear or a cytoplasmic luciferase expressed in murine cells was enhanced when cells had been pretreated with indomethacin. Additionally, in these cells the 70-kDa constitutive heat shock protein exhibited an enhanced aggregation in the presence of indomethacin. Similarly an increase in the aggregation of beta-galactosidase was observed. These data suggest that indomethacin at moderate temperatures accelerates the presence of denatured proteins in the cell, thus lowering the temperature threshold for a heat shock response.
 ...
PMID:Enhanced protein denaturation in indomethacin-treated cells. 1070 34

Glucose-6-phosphate dehydrogenase (G6PD) is involved in the generation of reduced nicotinamide adenine dinucleotide phosphate (NADPH) and the maintenance of the cellular redox balance. The biological effects of G6PD deficiency in nucleated cells were studied using G6PD-deficient human foreskin fibroblasts (HFF). In contrast to that of normal HFF, the doubling time of G6PD-deficient cells increased readily from population doubling level (PDL) 15 to 63. This was accompanied by a significant increase in the percentage of G(1) cells. The slow-down in growth preceded an early entry of these cells into a nondividing state reminiscent of cellular senescence. These cells exhibited a significant increase in level of senescence-associated beta-galactosidase (SA-beta-gal) staining. The importance of G6PD activity in cell growth was corroborated by the finding that ectopic expression of active G6PD in the deficient cells prevented their growth retardation and early onset of senescence. Mechanistically, the enhanced fluorescence in dichlorofluorescin (H(2)DCF)-stained G6PD-deficient cells suggests the possible involvement of reactive oxygen species in senescence. Taken together, our results show that G6PD deficiency predisposes human fibroblasts to retarded growth and accelerated cellular senescence. Moreover, G6PD-deficient HFF provides a useful model system for delineating the effects of redox alterations on cellular processes.
 ...
PMID:Enhanced oxidative stress and accelerated cellular senescence in glucose-6-phosphate dehydrogenase (G6PD)-deficient human fibroblasts. 1098 Apr 4